Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents.
- Author:
Yu-chen CAI
1
;
Yong ZOU
;
Li-jian XIAN
Author Information
1. State Key Laboratory of Oncology in South China, Guangzhou 510060, China.
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
chemistry;
pharmacology;
therapeutic use;
Animals;
Antineoplastic Agents;
chemistry;
pharmacology;
therapeutic use;
Bibenzyls;
chemistry;
pharmacology;
therapeutic use;
Diphosphates;
chemistry;
pharmacology;
therapeutic use;
Endothelial Cells;
drug effects;
Humans;
Molecular Structure;
Neoplasms;
drug therapy;
pathology;
Neovascularization, Pathologic;
Oligopeptides;
chemistry;
pharmacology;
therapeutic use;
Organophosphorus Compounds;
chemistry;
pharmacology;
therapeutic use;
Serine;
analogs & derivatives;
chemistry;
pharmacology;
therapeutic use;
Stilbenes;
chemistry;
pharmacology;
therapeutic use;
Tubulin Modulators;
chemistry;
pharmacology;
therapeutic use;
Xanthones;
chemistry;
pharmacology;
therapeutic use
- From:
Acta Pharmaceutica Sinica
2010;45(3):283-288
- CountryChina
- Language:Chinese
-
Abstract:
Vascular disrupting agents (VDAs) have presented a new kind of anti-cancer drug in recent years. VDAs take advantage of the weakness of established tumor endothelial cells and their supporting structures. In contrast to anti-angiogenic therapy, which inhibits the outgrowth of new blood vessels, vascular targeting treatments selectively attack the existing tumor vasculature. Here we summarized the anti-tumor activities, mechanisms and clinical applications of small molecule VDAs.
